BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jul 28, 2014
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
Company Bank Analyst Coverage Opinion Wk chg 7/25 cls
Gilead Sciences Inc. (NASDAQ:GILD) BMO Capital Markets Jim Birchenough Price target Outperform 1% $89.84
Birchenough raised his target to $165 from $123 on Gilead's strong 2Q14 results, continued strength of its HCV drug Sovaldi sofosbuvir and increased guidance. Last week, the...

Read the full 443 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >